HISTOPATHOLOGICAL FEATURES OF DENOSUMAB TREATED GIANT CELL TUMOURS OF BONE “A SINGLE INSTITUTIONAL EXPERIENCE” AT A TERTIARY CARE CENTER, KARACHI

Authors

  • Salima Mansoor Ali The Indus Hospital, Karachi
  • Nausheen Yaqoob The Indus Hospital
  • Kanwal Aftab The Indus Hospital
  • Samar Tauseef The Indus Hospital
  • Syed Kamran Ahmed The Indus Hospital
  • Syed Ali Anwar Jilani The Indus Hospital
  • Saba Jamal The Indus Hospital

Abstract

Background: Giant cell tumour (GCT) is a primary benign, locally aggressive bone tumour. Treatment is surgical however, denosumab has been increasingly used as a treatment in recurrent or unresectable locally advanced GCT because of its effect in reducing tumour size. Denosumab treated GCT can exhibit a wide array of histopathological features resulting in diagnostic problems for pathologists. Our study aimed at identifying these histopathological features to aid pathologists in reaching a correct diagnosis. Methods: Our study included 20 patients of biopsy-proven GCT cases treated with denosumab. We received specimens for histopathological examination in our institution from January 2018 to March 2020. The demographic and clinical data of these patients were retrieved from the Health Management Information System (HMIS). The slides were retrieved and studied for histopathological changes. Results: The mean age of patients in our study was 29.5 years. There were 11 males and 9 females. Distal radius was most commonly involved bone. On histopathological examination, ovoid to spindle mononuclear stromal cells were seen. Total absence of osteoclast like giant cells was seen in 10 (50%) cases, whereas 3 (15%) cases showed a marked reduction in osteoclast like giant cells. Conclusion: Denosumab treated GCT of bone can exhibit a wide spectrum of histopathological features. Pathologists need to be mindful of these features. Correlation of histopathological findings with clinical history and radiological features is important to prevent erroneous diagnosis. Treatment history of patients with denosumab is essential as incorrect diagnosis can be made if the history of denosumab treatment is not provided.

Author Biographies

Nausheen Yaqoob, The Indus Hospital

Head of Department of Histopathology

Kanwal Aftab, The Indus Hospital

Consultant Department of Histopathology

Samar Tauseef, The Indus Hospital

Resident Department of Histopathology

Syed Kamran Ahmed, The Indus Hospital

Professor and Senior consultant Department of Orthopaedics Surgery

Syed Ali Anwar Jilani, The Indus Hospital

Consultant Department of Orthopaedics Surgery

Saba Jamal, The Indus Hospital

Head of Department Blood Center

References

Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F. WHO Classification of Tumours of Soft Tissue and Bone, ed 4. Geneva, World Health Organization, 2013.

Unni KK, Inwards CY, Bridge JA, Kindblom LG, Wold LE. Tumours of the bones and joints. AFIP Atlas of Tumour Pathology. Fourth series, Fascicle 2. Washington, DC: AFIP; 2005.

Wojcik J, Rosenberg AE, Bredella MA, Choy E, Hornicek FJ, Nielsen GP et al. Denosumab-treated giant cell tumour of bone exhibits morphologic overlap with malignant giant cell tumour of bone. Am J Surg Pathol 2016;40:72–80.

Sobti A, Agrawal P, Agarwala S, Agarwal M. Giant cell tumour of bone-an overview. Arch Bone Jt Surg 2016;4(1):2–9.

Traub F, Singh J, Dickson BC, Leung S, Mohankumar R, Blackstein ME, et al. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone. Eur J Cancer 2016;59:1–12.

Tariq MU, Umer M, Khan Z, Saeed J, Siddiqui MA, Din NU. Spectrum of histological features of Denosumab treated Giant Cell Tumour of Bone; potential pitfalls and diagnostic challenges for pathologists. Ann Diagn Pathol 2020;45:151479.

Errani C, Tsukamoto S, Mavrogenis AF. How safe and effective is denosumab for bone giant cell tumour? Int Orthop 2017;41(11):2397–400.

Wu CC, Hsieh PP. Denosumab-treated giant cell tumour of the bone mimicking low-grade central osteosarcoma. J Pathol Transl Med 2018;52(2):133–5.

Gaston CL, Grimer RJ, Parry M, Stacchiotti S, Dei Tos AP, Gelderblom H, et al. Current status and unanswered questions on the use of Denosumab in giant cell tumour of bone. Clin Sarcoma Res 2016;6(1):15.

Agarwal MG, Gundavda MK, Gupta R, Reddy R. Does denosumab change the giant cell tumour treatment strategy? lessons learned from early experience. Clin Orthop Relat Res 2018;476(9):1773–82.

Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, et al. Denosumab, a fully human monoclonal antibody to RANKL inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009;24(2):182–95.

Müller DA, Beltrami G, Scoccianti G, Campanacci DA, Franchi A, Capanna R. Risks and benefits of combining denosumab and surgery in giant cell tumour of bone-a case series. World J Surg Oncol 2016;14(1):281.

Hakozaki M, Tajino T, Yamada H, Hasegawa O, Tasaki K, Watanabe K, et al. Radiological and pathological characteristics of giant cell tumour of bone treated with denosumab. Diagn Pathol 2014;9(1):111.

Roitman PD, Jauk F, Farfalli GL, Albergo JI, Aponte-Tinao LA. Denosumab-treated giant cell tumour of bone. Its histologic spectrum and potential diagnostic pitfalls. Hum Pathol 2017;63:89–97.

Rekhi B, Verma V, Gulia A, Jambhekar NA, Desai S, Juvekar SL, et al. Clinicopathological features of a series of 27 cases of post-denosumab treated giant cell tumours of bones: a single institutional experience at a tertiary cancer referral Centre, India. Pathol Oncol Res 2017;23(1):157–64.

Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, et al. Denosumab induces tumour reduction and bone formation in patients with giant-cell tumour of bone. Clin Cancer Res 2012;18(16):4415–24.

Alaqaili SI, Abduljabbar AM, Altaho AJ, Khan AA, Alherabi JA. Malignant sarcomatous transformation of benign giant cell tumour of bone after treatment with denosumab therapy: a literature review and reported cases. Cureus 2018;10(12):e3792.

Czerniak B. Dorfman and Czerniak's bone tumours. 2nd edition, Elsevier; 2016.

Niu X, Yang Y, Wong KC, Huang Z, Ding Y, Zhang W. Giant cell tumour of the bone treated with denosumab: How has the blood supply and oncological prognosis of the tumour changed? J Orthop Translat 2018;18:100–8.

Lipplaa A, Dijkstra S, Gelderblom H. Challenges of denosumab in giant cell tumour of bone, and other giant cell-rich tumours of bone. Curr Opin Oncol 2019;31(4):329.

Rosai, J. Rosai and Ackerman's Surgical Pathology. 11 ed. Elsevier, Lyon, France; 2011.

Rosenberg AE, Nielsen GP. Giant cell containing lesions of bone and their differential diagnosis. Curr Diagn Pathol 2001;7(4):235–46.

Alhumaid I, Abu-Zaid A. Denosumab therapy in the management of aneurysmal bone cysts: a comprehensive literature review. Cureus 2019;11(1):e3989.

Chakarun CJ, Forrester DM, Gottsegen CJ, Patel DB, White EA, Matcuk GR Jr. Giant cell tumour of bone: Review, mimics, and new developments in treatment. Radiographics 2013;33(1):197–211.

Downloads

Published

2022-01-01